The majority of adjudicated events were coronary revascularisations (10.3% Repatha; 13.6% placebo), followed by myocardial infarction (2.1% Repatha; 2.9% placebo).

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 ...

Sales of Repatha grew slowly since launch to reach around $150m in the second quarter of 2018, but have stayed pretty much static at that level since, with rising demand counterbalanced by price ...

Repatha, a cholesterol-lowering medication, has shown strong volume growth of 41% in recent quarters, highlighting its importance to Amgen’s stable business.

New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT ...

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 844-REPATHA (844-737-2842) regarding Repatha ® availability or find more information, including full Prescribing Information, at www ...

Across the recent three months, 8 analysts have shared their insights on Amgen (NASDAQ:AMGN), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotech player with a market capitalization of $152.7 billion and impressive 69% gross profit margins, revealed Monday that its ...

The rapid addition of small interfering RNA therapy to usual care after a recent ACS helps more patients achieve recommended LDL-cholesterol targets than does usual care alone, data from the VICTORION ...